Pino, M., Paiardini, M. & Marconi, V. C. Progress in achieving long-term HIV remission. Curr. Opin. HIV AIDS 13, 435–445 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Vanhamel, J., Bruggemans, A. & Debyser, Z. Establishment of latent HIV-1 reservoirs: what do we really know? J. Virus Erad. 5, 3–9 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lian, X. et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe 31, 83–96 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuo, H. H. & Lichterfeld, M. Recent progress in understanding HIV reservoirs. Curr. Opin. HIV AIDS 13, 137–142 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landovitz, R. J., Scott, H. & Deeks, S. G. Prevention, treatment and cure of HIV infection. Nat. Rev. Microbiol. 21, 657–670 (2023).

Article  CAS  PubMed  Google Scholar 

Reeves, D. B. et al. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat. Commun. 9, 4811 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Immonen, T. T. et al. No evidence for ongoing replication on ART in SIV-infected macaques. Nat. Commun. 15, 5093 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Evans, D. T. & Desrosiers, R. C. Immune evasion strategies of the primate lentiviruses. Immunol. Rev. 183, 141–158 (2001).

Article  CAS  PubMed  Google Scholar 

Boutwell, C. L., Rolland, M. M., Herbeck, J. T., Mullins, J. I. & Allen, T. M. Viral evolution and escape during acute HIV-1 infection. J. Infect. Dis. 202, S309–S314 (2010).

Article  PubMed  Google Scholar 

Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546–553 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garber, D. A., Silvestri, G. & Feinberg, M. B. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4, 397–413 (2004).

Article  CAS  PubMed  Google Scholar 

Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893–900 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Margolis, D. M. et al. Curing HIV: seeking to target and clear persistent infection. Cell 181, 189–206 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewin, S. R. & Rasmussen, T. A. Kick and kill for HIV latency. Lancet 395, 844–846 (2020).

Article  PubMed  Google Scholar 

Tanaka, K., Kim, Y., Roche, M. & Lewin, S. R. The role of latency reversal in HIV cure strategies. J. Med. Primatol. 51, 278–283 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Kim, Y., Anderson, J. L. & Lewin, S. R. Getting the “Kill” into “Shock and Kill”: strategies to eliminate latent HIV. Cell Host Microbe 23, 14–26 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alto, A. et al. The combination of venetoclax and ixazomib selectively and efficiently kills HIV-infected cell lines but has unacceptable toxicity in primary cell models. J. Virol. 95, e00138-21 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chandrasekar, A. P., Cummins, N. W. & Badley, A. D. The role of the BCL-2 family of proteins in HIV-1 pathogenesis and persistence. Clin. Microbiol. Rev. 33, e00107–e00119 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Cummins, N. W. et al. Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition. J. Virol. 91, e00012–e00017 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren, Y. et al. Selective BCL-XL antagonists eliminate infected cells from a primary-cell model of HIV latency but not from ex vivo reservoirs. J. Virol. 95, e0242520 (2021).

Article  PubMed  Google Scholar 

Ren, Y. et al. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J. Clin. Invest. 130, 2542–2559 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782–6789 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006–3015 (2001).

Article  CAS  PubMed  Google Scholar 

Vibholm, L. et al. Short-course Toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection. Clin. Infect. Dis. 64, 1686–1695 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890 (2014).

Article  CAS  PubMed  Google Scholar